Savara Inc. (NASDAQ: SVRA) began the trading day with its shares slightly in the green. The company, a clinical stage biopharmaceutical firm focused on rare respiratory diseases, today announced the amendment of its loan and security agreement with Hercules Capital, Inc. (NYSE:HTGC), strengthening its balance sheet and liquidity.
Under the terms of the amended loan agreement, up to an additional $75 million will become available upon FDA’s approval of MOLBREEVI, the Company’s investigational therapy in autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The loan agreement maturity date and interest-only period remain unchanged. There are no warrants in connection with the agreement.
“In anticipation of the potential approval of MOLBREEVI later this year, Savara will be well capitalized with ~$150 million of non-dilutive capital to support launch activities,” said Dave Lowrance, Chief Financial and Administrative Officer, Savara. “This includes the amended debt facility announced today combined with the strategic royalty financing from RTW announced in October last year.”
The Company resubmitted the MOLBREEVI Biologics License Application (BLA) to the FDA in December 2025. If Priority Review is granted, MOLBREEVI could potentially be approved in 3Q 2026. The Company remains on track to file the Marketing Authorization Applications (MAA) for MOLBREEVI in Europe and the U.K. by the end of 1Q 2026.
SVRA acquired eight cents, or 1.3%, to $5.86, while those for HTGC triumphed 18 cents to $18.72.
